Switch theme
Sign up to access all valuation multiples
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
2016
24
LTM Revenue $29.0M
Last FY EBITDA -$78.4M
-$5.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Black Diamond Therapeutics has a last 12-month revenue (LTM) of $29.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Black Diamond Therapeutics achieved revenue of n/a and an EBITDA of -$78.4M.
Black Diamond Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Black Diamond Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $29.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $29.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$78.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$77.7M | XXX | -$78.8M | XXX | XXX | XXX |
| EBIT Margin | -268% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$71.9M | XXX | -$69.7M | XXX | XXX | XXX |
| Net Margin | -248% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Black Diamond Therapeutics's stock price is $2.
Black Diamond Therapeutics has current market cap of $125M, and EV of -$5.7M.
See Black Diamond Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$5.7M | $125M | XXX | XXX | XXX | XXX | $-0.81 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Black Diamond Therapeutics has market cap of $125M and EV of -$5.7M.
Black Diamond Therapeutics's trades at n/a EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Black Diamond Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Black Diamond Therapeutics has a P/E ratio of -1.7x.
See valuation multiples for Black Diamond Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $125M | XXX | $125M | XXX | XXX | XXX |
| EV (current) | -$5.7M | XXX | -$5.7M | XXX | XXX | XXX |
| EV/Revenue | -0.2x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -0.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBlack Diamond Therapeutics's last 12 month revenue growth is 42%
Black Diamond Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $3.3M for the same period.
Black Diamond Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Black Diamond Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Black Diamond Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Black Diamond Therapeutics acquired XXX companies to date.
Last acquisition by Black Diamond Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Black Diamond Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Black Diamond Therapeutics founded? | Black Diamond Therapeutics was founded in 2016. |
| Where is Black Diamond Therapeutics headquartered? | Black Diamond Therapeutics is headquartered in United States of America. |
| How many employees does Black Diamond Therapeutics have? | As of today, Black Diamond Therapeutics has 24 employees. |
| Who is the CEO of Black Diamond Therapeutics? | Black Diamond Therapeutics's CEO is Dr. Mark A. Velleca, M.D.. |
| Is Black Diamond Therapeutics publicy listed? | Yes, Black Diamond Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Black Diamond Therapeutics? | Black Diamond Therapeutics trades under BDTX ticker. |
| When did Black Diamond Therapeutics go public? | Black Diamond Therapeutics went public in 2020. |
| Who are competitors of Black Diamond Therapeutics? | Similar companies to Black Diamond Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Black Diamond Therapeutics? | Black Diamond Therapeutics's current market cap is $125M |
| What is the current revenue of Black Diamond Therapeutics? | Black Diamond Therapeutics's last 12 months revenue is $29.0M. |
| What is the current revenue growth of Black Diamond Therapeutics? | Black Diamond Therapeutics revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Black Diamond Therapeutics? | Current revenue multiple of Black Diamond Therapeutics is -0.2x. |
| Is Black Diamond Therapeutics profitable? | Yes, Black Diamond Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
